News & Updates

Show Multimedia Only

Does MS relapse after stopping ponesimod?

17 Jul 2026 by

In a post hoc analysis of the OPTIMUM* long-term extension (OPTIMUM-LTE) study, discontinuation of ponesimod did not lead to a clinically meaningful disease reactivation or rebound effect in patients with relapsing multiple sclerosis (MS).

Does MS relapse after stopping ponesimod?

17 Jul 2026

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

17 Jul 2026

Children born to mothers who used paracetamol during pregnancy are unlikely to develop autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD), according to a study from Hong Kong.

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

17 Jul 2026

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

16 Jul 2026

Treatment with nanoencapsulated sirolimus plus pegadricase yields higher response rates compared with placebo in patients with uncontrolled gout, according to the phase III DISSOLVE I and II studies.

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

16 Jul 2026

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026 by

Elobixibat delivers superior symptom relief and quality-of-life improvements compared with prucalopride in the second-line treatment of patients with functional constipation, as shown in a head-to-head trial.

Elobixibat bests prucalopride for functional constipation in head-to-head trial

16 Jul 2026

Medication nonadherence more common in young vs older adults with SLE

16 Jul 2026

Self-reported medication nonadherence is greater among younger vs older adults with systemic lupus erythematosus (SLE), driven primarily by logistical barriers, reports a study.

Medication nonadherence more common in young vs older adults with SLE

16 Jul 2026

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026 by

In individuals receiving odevixibat for progressive familial intrahepatic cholestasis 2 (PFIC2), also known as bile salt export pump (BSEP) deficiency, reductions in serum bile acid (sBA) levels correlated with improvements in key liver function tests (LFTs), according to a post hoc subgroup analysis presented at ESPGHAN 2026.

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

16 Jul 2026

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

16 Jul 2026

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obstructive sleep apnoea (OSA) may reduce the incidence of cerebrovascular events, minimize healthcare use, and lower all-cause mortality, according to a retrospective study.

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

16 Jul 2026

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

16 Jul 2026

Protecting infants against RSV begins before birth. At a Pfizer-sponsored symposium during ESCMID Global 2026, experts reviewed the latest evidence on maternal RSV immunization, including disease burden, effectiveness, safety, and implementation. Presentations by Professors Marta Nunes, Paolo Manzoni, and Dr Olivia Anselem highlighted how maternal vaccination protects against severe RSV disease in early infancy. Professor Beate Kampmann chaired the session.

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

16 Jul 2026

Dextrose gel to prevent transitional neonatal hypoglycaemia may do more harm than good

15 Jul 2026

Administering a single dose of dextrose gel as prophylaxis against transitional neonatal hypoglycaemia does not help with the risk of neurocognitive impairment at early school age and even appears to have adverse effects on psychological well-being, according to a study.

Dextrose gel to prevent transitional neonatal hypoglycaemia may do more harm than good

15 Jul 2026

Short-cycle dosing of three-drug HIV regimen not a viable strategy for teens

15 Jul 2026 by

In adolescents living with HIV, a 5-days-on and 2-days-off dosing of antiretroviral therapy (ART) with tenofovir disoproxil fumarate, lamivudine, and dolutegravir fails to match the efficacy of continuous dosing for maintaining viral suppression, as shown in the BREATHER Plus trial conducted in Africa.

Short-cycle dosing of three-drug HIV regimen not a viable strategy for teens

15 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Does MS relapse after stopping ponesimod?

Does MS relapse after stopping ponesimod?

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

Prenatal paracetamol exposure cleared of ASD, ADHD risk in offspring

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

Nanoencapsulated sirolimus plus pegadricase helps patients with uncontrolled gout

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Elobixibat bests prucalopride for functional constipation in head-to-head trial

Medication nonadherence more common in young vs older adults with SLE

Medication nonadherence more common in young vs older adults with SLE

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

GLP-1 RAs confer cerebrovascular benefit in obstructive sleep apnoea

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Dextrose gel to prevent transitional neonatal hypoglycaemia may do more harm than good

Dextrose gel to prevent transitional neonatal hypoglycaemia may do more harm than good

Short-cycle dosing of three-drug HIV regimen not a viable strategy for teens

Short-cycle dosing of three-drug HIV regimen not a viable strategy for teens